| Ytd | -52.04% | |
| 1y | -50.58% |
| Open | 3.46 | Prev Close | 3.39 | Low | 3.41 | High | 3.50 | Mkt Cap | 29.67M |
| Vol | 40.81K | Avg Vol | 202.90K | EPS | -18.41 | P/E | -0.19 | Forward P/E | -1.38 |
| Beta | 1.14 | Short Ratio | 0.77 | Inst. Own | 4.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-16 | 50-d Avg | 3.35 | 200-d Avg | 5.51 | 1yr Est | 15.00 |
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins Br
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metast
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast c
PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinic
PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
Briacell Therap (NASDAQ: BCTX - Get Free Report) was the recipient of a large increase in short inte
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the comp
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) rose 73.6% to $9.65 in pre-market trading.
Gainers